Hypoxia-inducible factor prolyl 4-hydroxylases (HIF-P4Hs, also known as PHDs or EglNs) are 2 enzymes that act as cellular oxygen sensors. Inhibition of HIF-P4Hs leads to stabilization of hypoxia-3 inducible transcription factors (HIFs) which initiate a gene expression program that allows to cope 4 with low oxygen levels and to restore tissue oxygenation. This involves for example upregulation of 5 erythropoiesis and angiogenesis, modulation of inflammatory responses and reprogramming of 6 metabolism. Currently, several pharmacological HIF-P4H inhibitors are in clinical trials mainly for 7 renal anemia. However, recent data suggest that HIF-P4H inhibitors could also be considered to treat 8 metabolic disorders. Here we will discuss the potential of targeting HIF-P4Hs and the HIF pathway 9 for the treatment of obesity, metabolic syndrome, atherosclerosis and fatty liver diseases.
high fat diet (HFD) [19] . Haplodeficiency for HIF-P4H-2 (PHD2/EglN1), the most abundant 23 isoenzyme, associates with lower body weight [18] (Fig. 4) . Further, systemic reduction of it in HIF-24 P4H-2 hypomorphic mice, which display differing HIF1α and HIF2α stabilization in various tissues 25 [20, 21] , reduced body weight, adiposity and WAT inflammation, lowered hepatic cholesterol 26 synthesis, improved the HDL/LDL+VLDL ratio, amended glucose tolerance and insulin sensitivity 27 and protected against hepatic steatosis [6, 8] (Fig. 4 ). When these mice were crossed with LDLR 28 mutant mice protection against atherosclerosis was reported [8] (Fig. 4) . The hepatic HIF-P4H-29 2/HIF1 axis has also been reported to contribute to post-exercise metabolic homeostasis [22] . Global 30 HIF-P4H-3 (PHD3/EglN3) deficiency caused systemic hypotension [23] but no difference in body 31 weight [18] (Fig. 4) . By contrast, global inactivation of the HIF asparaginyl hydroxylase FIH (Fig. 1) 32 reduced body weight, elevated metabolic rate and improved glucose and lipid homeostasis, and 33 offered resistance to HFD-induced weight gain and hepatic steatosis [24] . Moreover, activation of 34 5 both HIF1 and HIF2 in adipocytes of mice by deleting a negative regulator, e.g. HIF-P4H-2, VHL 1 or FIH (Fig. 1) , reduces fat mass [6, [24] [25] [26] . Oppositely, endothelial cell-specific deficiency of HIF-2 P4H-2 increased body and fat weight, impaired glucose tolerance and induced hepatic steatosis and 3 fibrosis ( Fig. 4) [27] . 4 Interestingly, the findings from the genetic studies were partially reproduced by the preclinical 5 pharmacological pan HIF-P4H-1-3 inhibitor FG-4497. Treatment of C57Bl/6J mice with FG-4497 6 phenocopied protection against obesity and metabolic dysfunction seen in the HIF-P4H-2 7 hypomorphs [6] (Fig. 4) . FG-4497-treatment also reduced adiposity and improved glucose tolerance 8 in mice fed a HFD suggesting that in addition to prevention, it could be used for obesity treatment 9 [6] . Along with the improved metabolism, systemic FG-4497 treatment of Ldlr -/mice also reduced 10 aortic plaques, reduced inflammation in WAT and led to higher levels of autoantibodies targeting 11 oxidized-LDL [8] (Fig. 4) . 12 In clinical trials with renal anemia patients the HIF-P4H-1-3 inhibitor roxadustat not only 13 corrected anemia but also reduced serum cholesterol levels and improved the HDL/LDL ratio [28] 14 (Table 1) . Similar effects on serum lipids were reported by daprodustat [29] whereas vadadustat did 15 not alter serum cholesterol levels [30] (Table 1) , however, vadadustat and molidustat were associated 16 with lowered blood pressure [31, 32] (Table 1) . Altogether, data from preclinical, clinical and 17 epidemiological studies support that activation of the hypoxia response via HIF-P4H inhibition is a 18 powerful tool to regulate metabolism (Fig. 4) . So far, majority of the data associate HIF-P4H 19 inhibition to be beneficial for metabolic health (see Clinician's Corner).
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Hypoxia, HIFs and HIF-P4Hs in fatty liver disease 22 Fatty liver disease is characterized by an excessive accumulation of macro-or microvesicular lipid 23 droplets in the cytoplasm of hepatocytes. Commonly, the presence of lipid droplets in more than 5% 24 of hepatocytes is defined as steatosis [33] . The lipids, mainly triglycerides, can arise from diet, de 25 novo lipogenesis or fatty acids released and re-esterified from the adipose tissue. In addition, ethanol, 26 which in many Western cultures is consumed at a daily rate of 20-30 g, leads to formation of fatty 27 acids. Hence, any imbalance in triglyceride acquisition and removal in the hepatocytes can lead to 28 steatosis. Clinically fatty liver disease is categorized into non-alcoholic fatty liver disease (NAFLD) 29 and alcoholic fatty liver disease both of which can progress to fibrosis, cirrhosis and hepatocellular 30 carcinoma (HCC) [34] . Hypoxia, HIFs and HIF-P4Hs in nonalcoholic fatty liver disease (NAFLD) 33 6 NAFLD became a major health problem in adults and children, since it parallels the pandemic spread 1 of obesity, T2D and cardiovascular diseases [35] . Currently, the worldwide prevalence of NAFLD is 2 estimated to be ~24% [36] . NAFLD comprises a range of conditions including simple, still benign 3 steatosis and pathological nonalcoholic steatohepatitis (NASH). About 10-30 % NASH patients will 4 progress into cirrhosis and about 40-60% of the cirrhosis patients will develop HCC [37] . Despite 5 growing prevalence, the factors influencing NAFLD and progression to NASH, fibrosis, cirrhosis and 6 HCC are poorly understood. Apart from continued nutrient excess, insulin resistance, impaired 7 autophagy, endoplasmic reticulum stress and reactive oxygen species (ROS) formation [38, 39] , 8 hypoxia may occur and aggravate development and progression of NAFLD [40, 41] . The role of 9 hypoxia for steatosis development was also supported by a recent mathematical model [42] .
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Interestingly, steatosis and later cellular damage observed in NASH are mainly found in the less 11 oxygenated pericentral areas of the liver acinus ( Fig. 5 ). This goes in line with the concept of 12 "metabolic zonation" (Fig. 5) . In that concept, the metabolic capacities in the smallest functional unit, 13 the liver acinus, are found distributed in different zones which exist according to the proximity of the 14 portal triad and the O2 gradient ( Fig. 5) [43].
15
The occurring physiological oxygen gradient, among other morphogens, is considered to be a 16 major modulator of metabolic zonation [43, 44] . In line, it was shown that the expression of the fatty 17 acid synthase (FASN) can be induced by hypoxia [45] HIF1α and HIF2α target genes [47] . In line, hepatocyte-specific deletion of HIF2α in mice 24 ameliorated NAFLD after feeding either a choline-deficient L-amino acid-defined or a 25 methionine/choline-deficient diet [50] . The NAFLD reduction appeared to be mediated by down-26 regulated macrophage M1 polarizing histidine-rich glycoprotein (HRGP) expression [50] , which 27 links hepatocyte function with inflammation.
28
HIF2α appears not only to be a stronger regulator than HIF1α with respect to lipid storage and 29 insulin sensitivity [51] , but also with the lipid profile. Studies with hepatocyte-specific VHL, 30 VHL/HIF1α and VHL/HIF2α knockout mice revealed that HIF2α is the major driver of a selective 31 autophagy pathway, namely pexophagy [52] . Since peroxisomes account for about 20% of O2 32 consumption and 35% of H2O2 production in liver [53] , it is conceivable that cells reduce the number 33 of peroxisomes during hypoxia. As a consequence of the HIF2α-driven pexophagy, the decreased 7 peroxisomal metabolic activity and the HIF2α-mediated PPARα antagonism [52, 54] shift the lipid 1 profile to a pattern which is similar to that seen in patients with NAFLD [55] . Hence, a pattern 2 showing an increase of triglycerides with very long-chain and polyunsaturated fatty acids as well as 3 a decrease in docosahexaenoic and arachidonic acid [52, 55] . Moreover, the effects of HIF2α on 4 pexophagy were not restricted to normal hepatocytes. In particular a reduced number of peroxisomes 5 was found in clear cell renal cell carcinomas with high HIF2α levels [52] . Another layer of complexity 6 was added by a study linking stabilization of intestinal HIF2 with NAFLD. Here, deletion of HIF2α 7 from intestinal cells or the HIF2 specific inhibitor PT2385 prevented HFD-induced hepatic steatosis
In line with the substrate preference ( Fig. 1) , it was demonstrated that liver specific lack of HIF-10 P4H-2 induced HIF1α, whereas lack of HIF-P4H-3 primarily activated HIF2α, and that the apparent 11 severe hepatic steatosis in the HIF-P4H-2/HIF-P4H-3 double knockout mice was mainly the result of 12 HIF2α activation [57] . In addition to steatosis, the liver specific HIF-P4H triple knock-out mice had 13 hepatic vascular malformations and massive erythrocytosis induced by hepatic EPO expression. obtained upon oral administration of the HIF-P4H inhibitors REC2923 or roxadustat, and these 20 effects could be advantageous e.g. in T2D patients suffering from metformin-associated lactic 21 acidosis [60]. In addition, liver-specific HIF-P4H-3 deletion in mice was shown to improve insulin 22 signaling and to counteract diabetes [5] . Thereby, HIF-P4H-3 lack acted mainly through HIF2α 23 stabilization, which then increased insulin receptor substrate-2 (IRS2) transcription and insulin-24 dependent PKB/Akt activation. Interestingly, a further increase in HIF2α (and HIF1α), obtained by 25 additional HIF-P4H-1 and/or HIF-P4H-2 deletions caused liver steatosis and did not lead to additive 26 metabolic improvements [5] .
27
Another report, although not in liver, links HIF-P4H-2 inactivation with regulation of 28 glycolysis, glycogen storage and inflammation [61], the latter being a feature of NASH. In that study, . Hence, while the liver and kidney-specific lack of HIF-P4H-2 appear to be 33 8 beneficial under conditions such as HFD or lactic acidosis, the latter study suggests that in myeloid 1 cells it may aggravate inflammation.
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In summary, the role of HIF-P4Hs in NAFLD appears to be complex and not yet fully 3 understood. While the data mainly from liver/hepatocyte-specific settings with inhibition of all HIF-4 P4Hs or stabilization of HIF2 indicate a NAFLD promoting role, the data also suggest that 5 restricting the inhibition to selected HIF-P4H isoenzymes may have beneficial effects. About 30% of them will develop cirrhosis and ~10% of those will progress to HCC [37] . While 10 gender and ethnic specific differences exist, e.g. women are more susceptible to ALD than men, Given the common aspects between NAFLD and ALD, such as steatosis as result of HIF2α activation, 20 one could expect a similar role in ALD. However, studies with HIF2α in ALD are, to the best of our 21 knowledge, not yet available and only a few studies with respect to HIF1α in ALD are published.
22
In one study hepatocyte-specific deletion of HIF1α protected mice from liver damage and lipid 23 accumulation when fed an ethanol containing diet (habituation to a Lieber-DeCarli liquid diet with 24 5% ethanol (v/v) over a period of 2 weeks, then maintained on the 5% diet for 4 weeks). Vice versa, 25 hepatocyte-specific overexpression of degradation-resistant HIF1α resulted in hepatomegaly and 26 steatosis upon ethanol feeding [66] . By contrast, another study using the same animal model and 27 almost identical study protocol (Lieber-DeCarli liquid diet with increasing concentrations of ethanol 28 from 1%-4% within the first week, followed by 6% for a further 4 weeks) showed that hepatocyte- Upon fibrosis, the changed tissue architecture causes resistance to blood flow and hypoxia [70] .
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In fact, this coincides with expression of HIF targets in human liver [71] and HIF1α stabilization in 11 mouse models [72, 73] . While to date the participation of HIF2α in liver fibrosis was not really 12 investigated, some reports show that hypoxia mainly via HIF1α can regulate genes important for 13 collagen synthesis and angiogenesis in stellate cells [74] . With respect to the associated inflammation, 14 the chemokine receptor CXCR4 and its ligand, stromal cell-derived factor-1 (SDF-1), which both are 15 required for infiltration of inflammatory cells, are HIF-target genes [75] . Indeed, deletion of HIF1α 16 or HIF1β in cells of the myeloid lineage reduced bile duct ligation-induced fibrosis in mice [76] .
17
Another mechanism contributing to fibrosis is epithelial-mesenchymal transition (EMT).
18
HIF1α and HIF2α were shown to regulate EMT in HCC cells [77] via the Snail family [78, 79] .
19
Reports from the kidney show that HIF1-dependent mechanisms contribute to fibrogenesis by 20 inducing expression of Snail1 [80] and another HIF target Twist [81, 82] , hence implying that a 21 similar mechanism could also work in liver, however, direct evidence needs to be obtained.
22
Although the HIF-dependent regulation of Snail appears to be a driver of EMT and to promote 23 fibrosis and HCC, it may also represent an important feedback mechanism for NAFLD-associated 24 insulin resistance. A recent report showed that hepatocyte-specific deletion of Snail1 enhanced The possible involvement of the HIF system in HCC is also indirectly reflected by the currently 7 used therapies or phase III clinical trials against HCC. Drugs, such as sorafenib, regorafenib, 8 lenvatinib, cabozantinib and ramucirumab, target tyrosine kinase receptor family members binding 9 vascular endothelial growth factor, placental-derived growth factor, stem cell factor and stem cell-10 derived factor, which are virtually directly or indirectly regulated by hypoxia/HIFs [91, 92] . Although 11 this picture is not entirely complete since various other important players feed into the pathogenesis 12 of HCC, these findings suggest a supportive role of hypoxia and HIF1α in disease progression, 13 whereas the role of HIF2α appears to be conflicting. Two studies indicated that HIF2α promotes HCC 14 [86, 93] and another study reported that HIF2α inhibits HCC progression [94] . 15 When HCC induced with diethylnitrosamine was studied in HIF-P4H-2 haplodeficient (Hif-16 p4h-2 +/-) mice, these mice had more aggravated HCC growth potentially due to Notch activation [95] . 17 Importantly, the effects of HIF-P4H-2 haplodeficiency appeared to be a rather late event and 18 manifested during tumor nodule formation and not early on during neoplastic transformation [96] . 19 Interestingly, the Hif-p4h-2 +/mice appeared to be less prone for metastasis. Although not shown for 20 HCC, those mice generate less metastasis than wild-type upon transplantation of Hif-p4h-2 +/+ tumor 21 cells. These effects are due to an improved vessel architecture within the tumor mediated mainly via 22 HIF2α [97]. Moreover, metastasis was also reduced when the Hif-p4h-2 haplodeficiency was 23 introduced to a genetic breast cancer model (PyMT mice). Mechanistically, metastasis reduction was 24 the result of a decreased activation of cancer associated fibroblasts, and a HIF-independent reduction 25 of TGF-β1 release and matrix production [98] . In line, when testing the systemically administered 26 HIF-P4H pan-inhibitor ethyl-3,4-dihydroxybenzoate in a preclinical setting of extended partial 27 hepatectomy to remove colorectal liver metastases, it was found to augment liver regeneration [99] .
28
Conflicting data with respect to HIF-P4H-2 expression and HCC in human samples were 29 reported. One study associated high HIF-P4H-2 expression with larger and higher stage tumors and Interestingly, HIF-P4H-3 expression seems to be a favorable prognostic marker for patients with 33 HCC [102] since its downregulation in HCC was associated with more aggressive tumor behavior 34 11 and poor prognosis [103] . Altogether, the mechanisms involved in the progression of fatty liver 1 diseases to fibrosis/cirrhosis/HCC are many and involve not only the HIF system but also the cross-2 talk with various other signaling pathways. This likely represents an underlying cause for 3 contradictory appearing data on the roles of HIFs and HIF-P4Hs and call for more studies to draw 4 conclusions. Various lines of evidence indicate that hypoxia, inhibition of HIF-P4Hs and stabilization of HIFs are 2 causally linked to various aspects of metabolism ( Fig. 4) . Hence, disrupting that causal chain via HIF-3 P4H inhibition could be an efficacious therapeutic option to treat the global epidemic of obesity, 4 metabolic syndrome, T2D and fatty liver diseases. However, at the moment it is uncertain whether 5 the current HIF-P4H inhibitors, which have been optimized to induce erythropoiesis, can be of 6 ultimate benefit due to the pleiotropic and context dependent activities of the different HIFs in 7 particular, as well as lacking information on specific diseases, e.g. ALD. From the data reviewed 8 here, it appears that HIF-P4H inhibition could be beneficial with respect to obesity, metabolic 9 syndrome and hyperlipidemia and under conditions similar to T2D (Fig. 4) . Regarding NAFLD, a Moreover, the recent identification of non-HIF HIF-P4H substrates (Fig. 2) suggest existence 32 of several cross-talk options which may be of special interest in HCC given the potential opposing 33 13 actions of HIF1α and HIF2α in cancer progression [105] . Because of its poor prognosis, limited 1 treatment options and high risks of tumor recurrence and metastases [88] , it is important to better 2 understand the contribution of HIFs and the HIF-P4H system in the pathogenesis of HCC and its 3 preceeding entities fibrosis and cirrhosis. In particular, it would be extremely important to understand 4 at which stage and under which conditions either HIF or HIF-P4H inhibitory effects with or without 5 HIF stabilization would be of value for the treatment of fibrosis/cirrhosis or even HCC (see 6 Outstanding Questions). Considering this, HIF-P4H inhibitors that exploit differences in binding of 7 HIFs and non-HIF substrates would be of interest, but at current, it is unknown how difficult it will 8 be to develop those in a clinically acceptable manner. We apologize to all researchers who excellently contributed to the field and whose work could not be 2 cited due to space limitations. Inhibition of HIF-P4Hs, which act as molecular oxygen sensors, is the so far best understood 2 mechanism to regulate the oxygen sensing pathway. Are there HIF-independent HIF-P4H substrates that mediate effects on metabolism and which could 7 be targeted by even more selective HIF-P4H inhibitors?
8
Can F isoform agonists be used instead of HIF-P4H inhibitors to receive the same or more 9 selective effects? 10 Can HIF-P4H inhibition be achieved by other means than chemical antagonists, such as exposure to 11 high altitude or lowering of tissue oxygenation for example by manipulation of hemoglobin levels? are αβ-heterodimeric transcription factors which bind to hypoxia response elements (HREs) in 10 regulatory regions of genes. The HIF system regulates >300 genes to balance oxygen supply and 11 demand (for HIF target genes see [106] ). The three α-subunits, HIF1-3green, are labile under 12 29 normoxia, whereas the subunit (HIF1/ARNT) (rose) is stable. When oxygen is available, three 1 HIF-P4H isoenzymes (PHDs/EglNs) (orange) hydroxylate one or two proline residues (4-Hyp) in 2 HIF subunits, which marks them for ubiquitinylation by the von Hippel-Lindau (pVHL) protein 3 (yellow) and proteasomal degradation. The catalytic activity of HIF-P4Hs is highly dependent on 4 oxygen and hypoxia destabilizes HIF [107] . HIF-P4H-2 (PHD2/EglN1) is the most abundant 5 isoenzyme and the major one regulating HIFstability. In kidney, inactivation of HIF-P4H-2 was 6 sufficient to induce EPO expression while in brain pericytes and hepatocytes it required simultaneous 7 inactivation of HIF-P4Hs 2 and 3 or all HIF-P4Hs, respectively [57, 108] . FIH (magenta), which 8 shares the same reaction mechanism and cofactors with HIF-P4Hs but is less dependent on oxygen, 9 hydroxylates an asparagine residue in HIF1/2α. The hydroxyaspargine (Asn-OH) prevents binding 10 of transcriptional coactivators, like CBP/p300 (petrol), and therefore inhibits HIF target genes 11 expression. humans that share the same reaction mechanism but act on different substrates (proteins, DNA, RNA, 4 and fatty acids). They require Fe 2+ , 2-oxoglutarate (2-OG) and O2 as cofactors and hydroxylate 5 proline residues to 4-hydroxyproline (4-Hyp). One atom of oxygen becomes incorporated into the 6 substrate while 2-OG decarboxylates to succinate and CO2. HIF-P4Hs also require a reducing factor, 7 such as vitamin C, L-cysteine, reduced glutathione (GSH) or DTT [109] . Several naturally or 8 pathologically occurring 2-OG analogues, such as fumarate, succinate or S-2-hydroxyglutarate (S-9 2HG), have been shown to inhibit HIF-P4H catalytic activity competitively. The oncometabolite R-10 2HG, generated by cancer-associated isocitrate dehydrogenase variants, did not inhibit HIF-P4Hs but 
